Navigation Links
NeurogesX Receives European Commission Approval for Qutenza(TM)
Date:5/21/2009

g development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, NeurogesX' plans to seek and timing to obtain a commercial partner for Qutenza in Europe; the size, scope and growth of potential markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' product candidates and its plans with regard to seeking potential development partners for its early stage product pipeline. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to; positive results in clinical trials may not be sufficient to obtain FDA approval; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Ex
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... DUBLIN , Aug. 27, 2014 ... of the "Global Lactic Acid  (Biodegradable Polymer, ... - Trends & Forecasts to 2019" report ... the simplest hydroxyl-carboxylic acid with an asymmetrical carbon ... in the biodegradable polymer, food and beverage, personal ...
(Date:8/27/2014)... Belmont, Mass. (PRWEB) August 27, 2014 ... of top technology vendors,” said Ven Thangaraj, CEO of ... imaging solutions that are taking the imaging corelab market ... trial sponsors, corelabs and research organizations to efficiently and ... and prepare the data to be analyzed and read ...
(Date:8/27/2014)... 27, 2014 Flagship Biosciences LLC, a ... to the pharmaceutical and medical device industries, has announced ... fast growing company has consolidated its histology and tissue ... to Westminster, CO, just north of Denver. The ... W. 103rd Ave., Suite 100, Westminster, CO 80021 , ...
(Date:8/27/2014)...  ARCH Venture Partners, one of the largest ... of seed and early-stage advanced technology companies, today ... more than $400 million in subscriptions. ARCH Venture ... by more than $150 million. "The ... potential of our approach to finding and funding ...
Breaking Biology Technology:Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Flagship Biosciences Announces Relocation and Expansion 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... Imaging Diagnostic,Systems, Inc., (OTC Bulletin Board: IMDS), a ... recent study on CTLM is one of the featured,scientific ... Dr. Jin Qi,a radiologist at the Tianjin Medical ... her paper, "CTLM as an Adjunct to Mammography,in the ...
... strong pipeline makes the,Copenhagen Region biotech cluster well prepared for ... development, Denmark,ranks third in Europe. Only United Kingdom and Germany ... Also in term of pipeline growth Denmark has a ... countries in Europe. , ...
... 1 Collexis Holdings, Inc.,(OTC Bulletin Board: ... and,knowledge discovery software, announced today a partnership ... promote BiomedExperts.com,to the association,s 200+ membership base. ... primary professional network for,BioFlorida, helping to facilitate ...
Cached Biology Technology:Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference 2Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference 3Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe 2BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 2BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 3BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 4
(Date:8/27/2014)... University of Utah biologist agan Sekercioglu, who campaigns to ... nation,s highest science prize, which is similar to the ... five researchers picked for 2014 the top awards by ... Three researchers won the Science Award and two ... equivalent to the Science Award but for scientists who ...
(Date:8/27/2014)... entering what is described by the Volunteer Wildfire Services ... Eastern Cape provincial government warned residents in certain parts ... and veld fires. A high veld fire danger ... the coast in the Great Kei and Mnquma area. ... during thunderstorms. The thunderstorms bring lightning strikes and ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):University of Utah biologist wins Turkey's top science prize 2Potential therapy for incurable Charcot-Marie-Tooth disease 2
... advice twice is enough for patients to get the significant ... by doctors at St. Michael,s Hospital and the University of ... take their health into their own hands," said Dr. David ... the hospital,s Risk Factor Modification Centre. Dr. Jenkins is also ...
... same University of Washington researcher who used chemical sleuthing ... turned her attention to the scented air wafting from ... the journal Air Quality, Atmosphere and Health, ... scented liquid laundry detergent and scented dryer sheet contains ...
... M M E D I A T E ... Medicine Journal Stem cells derived from human amniotic fluid hold ... Tampa, Fla. (Aug. 24, 2011) Two papers published ... on-line at http://www.ingentaconnect.com/content/cog/ct/ , highlight the rich source of stem cells ...
Cached Biology News:No need to nag: study finds doctors' nutrition advice hits home early 2Scented laundry products emit hazardous chemicals through dryer vents 2Stem cells derived from human amniotic fluid hold promise 2Stem cells derived from human amniotic fluid hold promise 3